Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia

The exponential expansion of genomic data coupled with the lack of appropriate clinical categorization of the variants is posing a major challenge to conventional medications for many common and rare diseases. To narrow this gap and achieve the goals of personalized medicine, a collaborative effort...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine 2021-08, Vol.11 (9), p.877
Main Authors: Hindi, Nagham N., Alenbawi, Jamil, Nemer, Georges
Format: Article
Language:English
Subjects:
Apolipoproteins
Cardiovascular disease
Cholesterol
Coronary vessels
Dyslipidemia
Epigenetics
Genes
Genomes
Genomics
Genotype & phenotype
Hypercholesterolemia
Lipids
Lipoproteins
Metabolism
Mutation
Pharmacogenomics
Phenotypes
Precision medicine
Proteins
Rare diseases
Review
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The exponential expansion of genomic data coupled with the lack of appropriate clinical categorization of the variants is posing a major challenge to conventional medications for many common and rare diseases. To narrow this gap and achieve the goals of personalized medicine, a collaborative effort should be made to characterize the genomic variants functionally and clinically with a massive global genomic sequencing of “healthy” subjects from several ethnicities. Familial-based clustered diseases with homogenous genetic backgrounds are amongst the most beneficial tools to help address this challenge. This review will discuss the diagnosis, management, and clinical monitoring of familial hypercholesterolemia patients from a wide angle to cover both the genetic mutations underlying the phenotype, and the pharmacogenomic traits unveiled by the conventional and novel therapeutic approaches. Achieving a drug-related interactive genomic map will potentially benefit populations at risk across the globe who suffer from dyslipidemia.
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm11090877